Theory Paper IIIDrNB Cardiology – Theory Notes

BARE METAL STENTS (BMS): ROLE AND CLINICAL SCENARIOS

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ICORE CONCEPTS AND THE “DES REVOLUTION”

  • The Clinical Decline: Since the introduction of second- and third-generation Drug-Eluting Stents (DES), the clinical use of Bare Metal Stents (BMS) has declined to a very small fraction of all PCIs.
  • Pathophysiology of BMS Failure: Because BMS lack an antiproliferative drug coating (such as Sirolimus, Everolimus, or Zotarolimus), they are associated with high rates of In-Stent Restenosis (ISR) driven by uncontrolled vascular smooth muscle cell proliferation and neointimal hyperplasia.

IIHISTORICAL CLINICAL SCENARIOS FOR BMS

  • Short Dual Antiplatelet Therapy (DAPT) Requirement: Historically, BMS were selected when only 1 month of DAPT could be tolerated, whereas early first-generation DES required 6 to 12 months of DAPT:
  • High Bleeding Risk (HBR): Patients with active bleeding risks or those requiring long-term oral anticoagulation.
  • Urgent Non-Cardiac Surgery: Patients requiring major non-cardiac surgery within 4 to 6 weeks of PCI to minimize stent thrombosis during DAPT interruption.
  • Medication Non-Adherence: Patients deemed unable to comply with a prolonged 6-to-12-month DAPT regimen.

IIITHE PARADIGM SHIFT: THE OBSOLESCENCE OF BMS

  • Neutralization of the “Short-DAPT” BMS Advantage: Landmark randomized trials using contemporary thin-strut polymer-free or biocompatible-polymer DES proved that 1 month of DAPT is safe with modern DES, completely eliminating the historical rationale for BMS:
  • LEADERS FREE Trial: Proved that in High Bleeding Risk (HBR) patients treated with a strict 1-month DAPT regimen, a polymer-free Drug-Coated Stent (BioFreedom) was both safer and more effective (significantly lower clinically driven target lesion revascularization and MI) than a BMS.
  • ONYX ONE Trial: Demonstrated that a durable-polymer Zotarolimus-Eluting Stent (Resolute Onyx) was non-inferior to the BioFreedom stent with only 1 month of DAPT in HBR patients.
  • SENIOR Trial: Confirmed that in elderly patients aged 75 years or older, implanting a bioabsorbable-polymer DES with a short DAPT regimen (1 month in stable CAD, 6 months in ACS) significantly reduced Major Adverse Cardiovascular Events (MACE) and repeat revascularization compared to BMS.
  • MASTER DAPT Trial: Validated that abbreviated 1-month DAPT following biodegradable-polymer Sirolimus-Eluting Stent implantation in HBR patients was non-inferior for net and ischemic clinical events while significantly reducing major or clinically relevant non-major bleeding.
Landmark Trial Target Population Stent & DAPT Regimen Definitive Clinical Finding
LEADERS FREE High Bleeding Risk (HBR) patients BioFreedom (DCS) vs. BMS with 1-month DAPT BioFreedom superior to BMS for both efficacy (lower TLR) and safety (lower MI/stent thrombosis)
ONYX ONE High Bleeding Risk (HBR) patients Resolute Onyx (DES) with 1-month DAPT Proved safety and efficacy of polymer-based DES with 1-month DAPT in HBR cohorts
SENIOR Elderly patients (>= 75 years old) DES vs. BMS with 1- to 6-month DAPT DES significantly reduced MACE and repeat revascularization without increasing bleeding
MASTER DAPT High Bleeding Risk (HBR) patients Modern DES with 1-month vs. standard DAPT 1-month DAPT preserved ischemic protection while significantly reducing bleeding

IVCONTEMPORARY GUIDELINES AND RARE RESIDUAL SCENARIOS

  • Stent-Type-Independent DAPT Guidelines: Contemporary ESC and ACC/AHA guidelines recommend new-generation DES over BMS across all patient and lesion subsets (Class I), with DAPT duration dictated entirely by the patient’s ischemic versus bleeding risk profile (ARC-HBR criteria) rather than stent type.
  • Rare Residual Circumstances:
    • Severe Resource Constraints: Extremely resource-limited settings where DES are unavailable.
    • Documented Hypersensitivity: Extremely rare patients with documented severe allergy to specific antiproliferative drugs or polymers used on DES. (Note: Even in large-diameter vessels exceeding 4.0 mm, modern DES remain superior to BMS for preventing restenosis.)

VTHE INDIAN CLINICAL CONTEXT

  • Universal DES Coverage in Public Schemes: National and state public health insurance programs in India (such as Ayushman Bharat) and NPPA price caps cover modern Drug-Eluting Stents, rendering BMS virtually obsolete in both public and private Indian catheterization laboratories.
  • Managing the High-Bleeding-Risk Indian Patient: In elderly Indian patients or those at high risk for gastrointestinal bleeding, the evidence-based strategy is implantation of a modern DES followed by abbreviated 1-to-3-month DAPT (per the MASTER DAPT protocol) rather than implanting a BMS.

Key references

  • Urban P, Meredith IT, Abizaid A, et al. (LEADERS FREE Investigators): Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk, New England Journal of Medicine.
  • Varenne O, Cook S, Sideris G, et al. (SENIOR Investigators): Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial, The Lancet.
  • Valgimigli M, Frigoli E, Heg D, et al. (MASTER DAPT Investigators): Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk, New England Journal of Medicine.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.